Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
A trial shows that blinatumomab could be used in more ways to treat ALL
BLINCYTO® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after...
Development and future potential of the BiTE (bispecific T-cell engager) platform
Immuno-oncology is a way to treat cancer by using the body's immune system. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that binds...
Rare autoimmune disorder myasthenia gravis treated by CAR-T therapy
The modified CAR-T treatment, which stands for chimeric antigen receptor T-cell, was used by scientists. It could reduce myasthenia gravis symptoms for a longer time...
Talazoparib with enzalutamide is approved by FDA for HRR gene-mutated metastatic castration-resistant prostate cancer
The Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Glofitamab-gxbm is approved by FDA for selected relapsed or refractory large B-cell lymphomas
July 2023: The Food and Drug Administration gave accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise...
Olaparib with abiraterone and prednisone (or prednisolone) is approved by FDA for BRCA-mutated metastatic castration-resistant prostate cancer
July 2023: The Food and Drug Administration (FDA) approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and prednisone (or prednisolone) for adults with deleterious or...
Epcoritamab-bysp is approved by FDA for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
July 2023: The Food and Drug Administration gave accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL)...
Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy
Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and...
Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma
For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and...
Omidubicel is approved by USFDA to reduce time to neutrophil recovery and infection in patients with hematologic malignancies
Omidubicel-onlv (Omisirge, Gamida Cell Ltd.) was approved by the Food and Drug Administration for use in adult and paediatric patients (12 years of age and...
Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma
Enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck) have been given accelerated approval by the Food and Drug Administration for the treatment of patients...
Retifanlimab-dlwr is approved by FDA for metastatic or recurrent locally advanced Merkel cell carcinoma
Retifanlimab-dlwr (Zynyz, Incyte Corporation) received fast approval from the Food and Drug Administration to treat adult patients with metastatic or recurrent locally advanced Merkel cell...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.